1. Introduction
1.1 Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Market Insights
2.2 Market Attractiveness
3. Research Methodology
3.1 Secondary Research
3.2 Primary Research
- 3.2.1 Data Triangulation and Validation
4. North America Therapeutic Vaccines Market Landscape
4.1 Overview
4.3 Ecosystem Analysis
- 4.3.1 List of Vendors in the Value Chain
5. North America Therapeutic Vaccines Market – Key Market Dynamics
5.1 Market Drivers
5.2 Market Restraints
5.3 Market Opportunities
5.4 Future Trends
5.5 Impact of Drivers and Restraints
6. North America Therapeutic Vaccines Market Regional Analysis
6.2 North America Therapeutic Vaccines Market Revenue 2021-2031 (US$ Thousand)
6.3 North America Therapeutic Vaccines Market Forecast Analysis
7. North America Therapeutic Vaccines Market Analysis – by Product
7.1 Cancer Vaccine
- 7.1.1 Overview
- 7.1.2 Cancer Vaccine: North America Therapeutic Vaccines Market – Revenue and Forecast, 2021-2031 (US$ Thousand)
7.2 Infectious Disease Vaccine
- 7.2.1 Overview
- 7.2.2 Infectious Disease Vaccine: North America Therapeutic Vaccines Market – Revenue and Forecast, 2021-2031 (US$ Thousand)
7.3 Others
- 7.3.1 Overview
- 7.3.2 Others : North America Therapeutic Vaccines Market – Revenue and Forecast, 2021-2031 (US$ Thousand)
8. North America Therapeutic Vaccines Market Analysis – by Technology
8.1 Allogenic Vaccine and Autologus Vaccine
- 8.1.1 Overview
- 8.1.2 Allogenic Vaccine and Autologus Vaccine: North America Therapeutic Vaccines Market – Revenue and Forecast, 2021-2031 (US$ Thousand)
9. North America Therapeutic Vaccines Market Analysis – by End User
9.1 Hospitals
- 9.1.1 Overview
- 9.1.2 Hospitals: North America Therapeutic Vaccines Market – Revenue and Forecast, 2021-2031 (US$ Thousand)
9.2 Clinics
- 9.2.1 Overview
- 9.2.2 Clinics: North America Therapeutic Vaccines Market – Revenue and Forecast, 2021-2031 (US$ Thousand)
9.3 Others
- 9.3.1 Overview
- 9.3.2 Others : North America Therapeutic Vaccines Market – Revenue and Forecast, 2021-2031 (US$ Thousand)
10. North America Therapeutic Vaccines Market – North America Analysis
10.1 Overview
10.2 North America
- 10.2.1 North America Therapeutic Vaccines Market Breakdown, by Key
Country, 2024 and 2031 (%)
- 10.2.1.1 North America Therapeutic Vaccines Market – Revenue and
Forecast Analysis – by Country
- 10.2.1.1 US:
North America Therapeutic Vaccines Market – Revenue and Forecast to 2031 (US$ Thousand)
- 10.2.1.1.1 US: North America Therapeutic Vaccines Market Breakdown, by Product
- 10.2.1.1.2 US: North America Therapeutic Vaccines Market Breakdown, by Technology
- 10.2.1.1.3 US: North America Therapeutic Vaccines Market Breakdown, by End User
- 10.2.1.2 Canada:
North America Therapeutic Vaccines Market – Revenue and Forecast to 2031 (US$ Thousand)
- 10.2.1.2.1 Canada: North America Therapeutic Vaccines Market Breakdown, by Product
- 10.2.1.2.2 Canada: North America Therapeutic Vaccines Market Breakdown, by Technology
- 10.2.1.2.3 Canada: North America Therapeutic Vaccines Market Breakdown, by End User
- 10.2.1.3 Mexico:
North America Therapeutic Vaccines Market – Revenue and Forecast to 2031 (US$ Thousand)
- 10.2.1.3.1 Mexico: North America Therapeutic Vaccines Market Breakdown, by Product
- 10.2.1.3.2 Mexico: North America Therapeutic Vaccines Market Breakdown, by Technology
- 10.2.1.3.3 Mexico: North America Therapeutic Vaccines Market Breakdown, by End User
11. Competitive Landscape
11.1 Heat Map Analysis
11.2 Company Positioning and Concentration
12. Industry Landscape
12.1 Overview
12.2 Market Initiative
12.3 Partnerships and Collaborations
12.4 Other Developments
13. Company Profiles
13.1 Dendreon
- 13.1.1 Key Facts
- 13.1.2 Business Description
- 13.1.3 Products and Services
- 13.1.4 Financial Overview
- 13.1.5 SWOT Analysis
- 13.1.6 Key Developments
13.2 BioNTech SE
- 13.2.1 Key Facts
- 13.2.2 Business Description
- 13.2.3 Products and Services
- 13.2.4 Financial Overview
- 13.2.5 SWOT Analysis
- 13.2.6 Key Developments
13.3 Serum Institute of India Pvt. Ltd
- 13.3.1 Key Facts
- 13.3.2 Business Description
- 13.3.3 Products and Services
- 13.3.4 Financial Overview
- 13.3.5 SWOT Analysis
- 13.3.6 Key Developments
13.4 Merck & Co Inc
- 13.4.1 Key Facts
- 13.4.2 Business Description
- 13.4.3 Products and Services
- 13.4.4 Financial Overview
- 13.4.5 SWOT Analysis
- 13.4.6 Key Developments
13.5 Amgen Inc
- 13.5.1 Key Facts
- 13.5.2 Business Description
- 13.5.3 Products and Services
- 13.5.4 Financial Overview
- 13.5.5 SWOT Analysis
- 13.5.6 Key Developments
13.6 ISA Pharmaceuticals BV
- 13.6.1 Key Facts
- 13.6.2 Business Description
- 13.6.3 Products and Services
- 13.6.4 Financial Overview
- 13.6.5 SWOT Analysis
- 13.6.6 Key Developments
13.7 INOVIO Pharmaceuticals Inc
- 13.7.1 Key Facts
- 13.7.2 Business Description
- 13.7.3 Products and Services
- 13.7.4 Financial Overview
- 13.7.5 SWOT Analysis
- 13.7.6 Key Developments
13.8 Transgene SA
- 13.8.1 Key Facts
- 13.8.2 Business Description
- 13.8.3 Products and Services
- 13.8.4 Financial Overview
- 13.8.5 SWOT Analysis
- 13.8.6 Key Developments
13.9 THERAVECTYS SA
- 13.9.1 Key Facts
- 13.9.2 Business Description
- 13.9.3 Products and Services
- 13.9.4 Financial Overview
- 13.9.5 SWOT Analysis
- 13.9.6 Key Developments
13.10 CureVac SE
- 13.10.1 Key Facts
- 13.10.2 Business Description
- 13.10.3 Products and Services
- 13.10.4 Financial Overview
- 13.10.5 SWOT Analysis
- 13.10.6 Key Developments
14. Appendix
14.1 About Business Market Insights
14.2 List of Abbreviations
Get Free Sample For North America Therapeutic Vaccines Market
